63.54
2.17 (3.54%)
| 前收盘价格 | 61.37 |
| 收盘价格 | 61.12 |
| 成交量 | 1,852,283 |
| 平均成交量 (3个月) | 1,917,825 |
| 市值 | 7,768,713,728 |
| 价格/销量 (P/S) | 83.75 |
| 股市价格/股市净资产 (P/B) | 60.31 |
| 52周波幅 | |
| 利润日期 | 5 Nov 2025 |
| 营业利益率 (TTM) | -9,856.30% |
| 稀释每股收益 (EPS TTM) | -5.29 |
| 季度收入增长率 (YOY) | 89.10% |
| 总债务/股东权益 (D/E MRQ) | 727.94% |
| 流动比率 (MRQ) | 5.99 |
| 营业现金流 (OCF TTM) | -398.00 M |
| 杠杆自由现金流 (LFCF TTM) | -241.41 M |
| 资产报酬率 (ROA TTM) | -34.12% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Cytokinetics, Incorporated | 看涨 | 看跌 |
AIStockmoo 评分
| 分析师共识 | 1.5 |
| 内部交易活动 | -1.0 |
| 价格波动 | -0.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -0.5 |
| 平均 | -0.10 |
|
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 0.72% |
| 机构持股比例 | 119.58% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 136.00 (HC Wainwright & Co., 114.04%) | 购买 |
| 中 | 89.00 (40.07%) | |
| 低 | 71.00 (Morgan Stanley, 11.74%) | 购买 |
| 平均值 | 93.25 (46.76%) | |
| 总计 | 8 购买 | |
| 平均价格@调整类型 | 64.53 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Morgan Stanley | 23 Dec 2025 | 71.00 (11.74%) | 购买 | 63.29 |
| Barclays | 22 Dec 2025 | 87.00 (36.92%) | 购买 | 65.60 |
| 06 Oct 2025 | 82.00 (29.05%) | 购买 | 60.64 | |
| Citizens | 22 Dec 2025 | 88.00 (38.50%) | 购买 | 65.60 |
| HC Wainwright & Co. | 22 Dec 2025 | 136.00 (114.04%) | 购买 | 65.60 |
| Needham | 22 Dec 2025 | 84.00 (32.20%) | 购买 | 65.60 |
| 12 Dec 2025 | 72.00 (13.31%) | 购买 | 63.35 | |
| RBC Capital | 22 Dec 2025 | 95.00 (49.51%) | 购买 | 65.60 |
| 11 Nov 2025 | 87.00 (36.92%) | 购买 | 66.50 | |
| Goldman Sachs | 19 Dec 2025 | 95.00 (49.51%) | 购买 | 62.72 |
| B. Riley Securities | 10 Nov 2025 | 90.00 (41.64%) | 购买 | 62.20 |
| 显示更多 | ||||
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| BLUM ROBERT I | 65.60 | 65.60 | -21,831 | -1,432,114 |
| CALLOS ANDREW | 65.60 | 63.68 | 693 | 52,425 |
| LEE SUNG | 65.60 | 65.60 | 3,499 | 229,534 |
| MALIK FADY IBRAHAM | 65.60 | 65.60 | 2,984 | 195,750 |
| WIERENGA WENDELL | - | 65.60 | -20,000 | -1,312,000 |
| 累积净数量 | -34,655 | |||
| 累积净值 ($) | -2,266,403 | |||
| 累积平均购买 ($) | 65.60 | |||
| 累积平均卖出 ($) | 65.05 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| CALLOS ANDREW | 职员 | 29 Dec 2025 | 卖 (-) | 1,809 | 61.75 | 111,706 |
| WIERENGA WENDELL | 董事 | 22 Dec 2025 | 卖 (-) | 20,000 | 65.60 | 1,312,000 |
| WIERENGA WENDELL | 董事 | 22 Dec 2025 | 执行期权 | 20,000 | - | - |
| BLUM ROBERT I | 职员 | 22 Dec 2025 | 处理 (-) | 30,426 | 65.60 | 1,995,946 |
| BLUM ROBERT I | 职员 | 22 Dec 2025 | 执行期权 | 71,233 | - | - |
| LEE SUNG | 职员 | 22 Dec 2025 | 获得 (+) | 4,304 | 65.60 | 282,342 |
| LEE SUNG | 职员 | 22 Dec 2025 | 处理 (-) | 805 | 65.60 | 52,808 |
| CALLOS ANDREW | 职员 | 22 Dec 2025 | 获得 (+) | 3,177 | 65.60 | 208,411 |
| CALLOS ANDREW | 职员 | 22 Dec 2025 | 处理 (-) | 675 | 65.60 | 44,280 |
| MALIK FADY IBRAHAM | 职员 | 22 Dec 2025 | 获得 (+) | 4,000 | 65.60 | 262,400 |
| MALIK FADY IBRAHAM | 职员 | 22 Dec 2025 | 处理 (-) | 1,016 | 65.60 | 66,650 |
| BLUM ROBERT I | 职员 | 22 Dec 2025 | 获得 (+) | 11,530 | 65.60 | 756,368 |
| BLUM ROBERT I | 职员 | 22 Dec 2025 | 处理 (-) | 2,935 | 65.60 | 192,536 |
| 显示更多 | ||||||
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合